RenovoRx Inc
NASDAQ:RNXT
RenovoRx Inc
NASDAQ:RNXT
Price:
0.8332
USD
-5.51%
Market Closed
Market Cap:
$30.5m
Relative Value
The Relative Value of one
RNXT
stock under the Base Case scenario is
1.1364
USD.
Compared to the current market price of 0.8332 USD,
RenovoRx Inc
is
Undervalued by 27%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
RNXT
Relative Value
Base Case
1.1364
USD
Undervaluation 27%
Multiples Across Competitors
RNXT Competitors Multiples
RenovoRx Inc Competitors
RenovoRx Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
RenovoRx Inc
NASDAQ:RNXT
|
30.5m USD | 32.9 | -2.7 | -1.8 | -1.8 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
417.5B USD | 6.8 | 99.9 | 16.3 | 22.6 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
204.7B USD | 5.6 | 26.5 | 15.2 | 15.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
184.3B USD | 6.3 | 21.7 | 13.5 | 16.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
121.5B USD | 10.1 | 30.7 | 23.2 | 24.2 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
83.1B USD | 5.8 | 18.5 | 13.9 | 15.9 | |
| AU |
|
CSL Ltd
ASX:CSL
|
70.1B AUD | 3.2 | 35.7 | 11.7 | 14.7 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
39.3B EUR | 11.2 | 35.8 | 39 | 39.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
